Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rifampin

W E Sanders

    Annals of Internal Medicine
    |July 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Rifampin, approved for tuberculosis and meningitis, shows promise for extrapulmonary TB, leprosy, and other infections. While it can cause proteinuria and immune suppression, these effects are generally minor and manageable.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

    Journal of clinical microbiology·2001
    Same author

    Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning operations for d-transposition of the great arteries.

    Journal of the American College of Cardiology·2000
    Same author

    Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

    Journal of clinical microbiology·2000
    Same author

    A pilot study of antibiotic cycling in a hematology-oncology unit.

    Infection control and hospital epidemiology·2000
    Same author

    Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.

    Antimicrobial agents and chemotherapy·1998
    Same author

    Ischaemia of the index finger and thumb secondary to thrombosis of the radial artery in the anatomical snuffbox.

    Journal of hand surgery (Edinburgh, Scotland)·1998
    Same journal

    Correction to I.M. Matters News: Sleep medicine for seniors.

    Annals of internal medicine·2026
    Same journal

    Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

    Annals of internal medicine·2026
    Same journal

    Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

    Annals of internal medicine·2026
    Same journal

    Grappling with GLP-1 prescribing.

    Annals of internal medicine·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Immunology

    Background:

    • Rifampin was approved in 1971 for pulmonary tuberculosis and Neisseria meningitidis carriers.
    • Current approved indications for rifampin remain unchanged.
    • Rifampin is a key antibiotic in treating various bacterial infections.

    Purpose of the Study:

    • To review the current and potential therapeutic applications of rifampin.
    • To discuss the immunological effects and adverse reactions associated with rifampin.
    • To explore the future utility of rifampin and its derivatives in treating infectious and malignant diseases.

    Main Methods:

    • Review of clinical trial data and established medical literature.
    • Analysis of rifampin's efficacy in extrapulmonary tuberculosis and leprosy.

    Related Experiment Videos

  • Examination of rifampin's impact on immune responses and associated adverse events.

    • Main Results:

    • Rifampin, combined with other drugs, shows value in extrapulmonary tuberculosis and other mycobacterial infections.
    • Clinical trials in leprosy have yielded encouraging results.
    • Rifampin can induce light chain proteinuria and suppress immune responses, but these effects are typically inconsequential.
    • Immunologically mediated reactions are linked to irregular drug administration and may be preventable.
    • Hepatic toxicity associated with rifampin may also be preventable.

    Conclusions:

    • Rifampin holds significant therapeutic potential beyond its current indications, including for extrapulmonary tuberculosis, leprosy, and other susceptible mycobacterial infections.
    • Adverse effects like proteinuria and immune suppression appear manageable and of little clinical consequence.
    • Preventable adverse reactions and hepatic toxicity highlight the importance of proper drug administration.
    • Rifampin and its congeners may offer future treatment options for a range of infectious and potentially malignant conditions.